PMID- 37090461
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1885-642X (Print)
IS  - 1886-3655 (Electronic)
IS  - 1885-642X (Linking)
VI  - 21
IP  - 1
DP  - 2023 Jan-Mar
TI  - Evaluating the clinical application of the immune cells' ratios and inflammatory 
      markers in the diagnosis of inflammatory bowel disease.
PG  - 2755
LID - 10.18549/PharmPract.2023.1.2755 [doi]
LID - 2755
AB  - OBJECTIVE: Inflammatory Bowel Diseases (IBDs) are chronic inflammatory conditions 
      of the gastrointestinal tract, including Crohn's disease (CD) and ulcerative 
      colitis (UC). Developing methods for effective screening and diagnosis is 
      extremely needed. Accordingly, this study aims to evaluate the potential of 
      immune cells ratios in the diagnosis of IBD. METHODS: This case-control study 
      includes data from Jordan University Hospital (JUH) medical records for IBD 
      patients with age- and gender-matched healthy controls. RESULTS: This study 
      included 46 participants, of which 56.52% had IBD, 54.35% were males, with 
      insignificant differences in sex, age, and body mass index (BMI) between IBD 
      patients and controls (p>0.05). In the CD group, the variables with the highest 
      sensitivity and specificity (HSS) were neutrophil-to-lymphocyte (NLR) (75%, 80%) 
      and platelet-to-lymphocytes (PLR) (75%, 90%), in UC group; mean corpuscular 
      hemoglobin (MCH) (80%, 80%). In CD group, the combinations giving the HSS were 
      PLR+NLR (76%, 90.9%), C-reactive protein (CRP)+PLR (76%, 90.9%), and CRP+NLR 
      (73.07%, 90%). In UC group, the combinations giving the HSS were erythrocyte 
      sedimentation rate (ESR)+PLR (76.9%, 100%), PLR+MCH (74.07%, 100%), PLR+CRP 
      (71.42%, 100%), and PLR+NLR (71.42%, 100%). Regression analysis identified five 
      different combinations of significance in the diagnosis of CD and UC. Higher 
      Youden's index was used and defined the most beneficial clinical combinations as 
      NLR+PLR and CRP+PLR for CD, whereas ESR+PLR for UC. CONCLUSION: Implications to 
      our study include the clinical application of immune cell ratios, inflammatory 
      markers, and their different combinations along with patients' history and 
      physical examination findings for easier, faster, and more cost-effective 
      diagnosis of IBDs.
CI  - Copyright: (c) Pharmacy Practice.
FAU - Al-Rshaidat, Mamoon M D
AU  - Al-Rshaidat MMD
AUID- ORCID: 0000-0003-3047-5608
AD  - Department of Biological, Sciences, Laboratory for Molecular & Microbial Ecology 
      (LaMME), School of Sciences, The University of Jordan, Amman 11942, Jordan. 
      m.rshaidat@ju.edu.jo.
FAU - Al-Sharif, Shaima
AU  - Al-Sharif S
AD  - Department of Biological, Sciences, School of Sciences, The University of Jordan, 
      Amman 11942, Jordan. shaimas1999@gmail.com.
FAU - Refaei, Assem Al
AU  - Refaei AA
AD  - School of Medicine, The University of Jordan, Amman 11942, Jordan. 
      Assem12963@gmail.com.
FAU - Shewaikani, Nour
AU  - Shewaikani N
AD  - School of Medicine, The University of Jordan, Amman 11942, Jordan. 
      shewaikani.nour@gmail.com.
FAU - Alsayed, Ahmad R
AU  - Alsayed AR
AUID- ORCID: 0000-0002-1324-7884
AD  - Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied 
      Science Private University, Amman 11931-166, Jordan. a_alsayed@asu.edu.jo.
FAU - Rayyan, Yaser M
AU  - Rayyan YM
AD  - School of Medicine, The University of Jordan, Amman 11942, Jordan. 
      Y.Rayyan@ju.edu.jo.
LA  - eng
PT  - Journal Article
DEP - 20221108
PL  - Spain
TA  - Pharm Pract (Granada)
JT  - Pharmacy practice
JID - 101530029
PMC - PMC10117338
OTO - NOTNLM
OT  - Crohn's disease
OT  - IBD
OT  - biomarkers
OT  - immune cells
OT  - inflammation
OT  - neutrophil-to-lymphocyte
OT  - platelet-to-lymphocytes
OT  - ulcerative colitis
EDAT- 2023/04/24 06:41
MHDA- 2023/04/24 06:42
PMCR- 2023/01/01
CRDT- 2023/04/24 03:41
PHST- 2022/10/03 00:00 [received]
PHST- 2022/10/20 00:00 [accepted]
PHST- 2023/04/24 06:42 [medline]
PHST- 2023/04/24 06:41 [pubmed]
PHST- 2023/04/24 03:41 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - pharmpract-21-2755 [pii]
AID - 10.18549/PharmPract.2023.1.2755 [doi]
PST - ppublish
SO  - Pharm Pract (Granada). 2023 Jan-Mar;21(1):2755. doi: 
      10.18549/PharmPract.2023.1.2755. Epub 2022 Nov 8.